Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

The majority of diffuse large B-cell lymphoma (DLBCL) tumors contain mutations in histone-modifying enzymes (HMEs), indicating a potential therapeutic benefit of histone deacetylase inhibitors (HDIs), and preclinical data suggest that HDIs augment the effect of rituximab. In this randomized phase 2...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Assouline, Sarit E., Nielsen, Torsten Holm, Yu, Stephen, Alcaide, Miguel, Chong, Lauren, MacDonald, David, Tosikyan, Axel, Kukreti, Vishal, Kezouh, Abbas, Petrogiannis-Haliotis, Tina, Albuquerque, Marco, Fornika, Daniel, Alamouti, Sepideh, Froment, Remi, Greenwood, Celia M. T., Oros, Kathleen Klein, Camglioglu, Errol, Sharma, Ayushi, Christodoulopoulos, Rosa, Rousseau, Caroline, Johnson, Nathalie, Crump, Michael, Morin, Ryan D., Mann, Koren K.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2016
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4972610/
https://ncbi.nlm.nih.gov/pubmed/27166360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-02-699520
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares